Please login to the form below

Ionis

This page shows the latest Ionis news and features for those working in and with pharma, biotech and healthcare.

UniQure cleared to start Huntington gene therapy trial

Meanwhile, Roche and Ionis have positive phase 1/2 results with an antisense drug called RG6042 that blocks the huntingtin gene from making the protein and recently started a pivotal trial

Latest news

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

Tegsedi from Akcea (a subsidiary of Ionis).
Biogen picks up another drug from wide-ranging Ionis alliance

" />. Aims to follow success of Spinraza. Biogen’s longstanding collaboration with Ionis has already resulted in one marketed drug – Spinraza – and it’s now taken up rights to another for amyotrophic ... Under the terms of the deal, Ionis
Novartis and Pfizer to collaborate on NASH combinations

Novo Nordisk and Bristol-Myers Squibb are also all active in the field, while AstraZeneca has been busy this year signing new collaborations with the likes of Ionis.
Alnylam gets EU nod for Onpattro amid pricing backlash

Ionis and Akcea secured EMA approval last month for their antisense candidate Tegsedi (inotersen), but are still in the process of negotiating price and reimbursement with individual EU countries, while ... Neither Tegsedi or Vyndaqel are approved yet in
ICER says Alnylam’s Onpattro should cost 90%-95% less

In draft guidance, the Institute for Clinical and Economic Review (ICER) says that RNA interference drug Onpattro (patisiran) – and Akcea/Ionis’ antisense candidate Tegsedi (inotersen) which is due for an FDA

More from news
Approximately 12 fully matching, plus 20 partially matching documents found.

Latest Intelligence

Deal Watch October 2018

Joint development using SQZ’s cell therapy. platform. $1.375B. Option. Ionis. RNA‐targeted therapeutics for complement mediated. ... RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

While Onpattro has outshone Ionis’ product in safety and efficacy, analysts see Onpattro’s lack of cardiovascular claims in its US label as a weak point. ... England’s NICE is just beginning its review of Onpattro (in tandem with a review of
The European Medicines Agency: PRIME’d for access?

Since March 2018 Roche, with Ionis, have added another PRIME drug to their portfolio. ... RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease.
Deal Watch February 2017

Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... As part of the agreement Ionis will also expand the collaboration
Deal Watch January 2017

As you sow, so shall you reap The use of options is remaining widespread as noted in the Novartis deal with Ionis and Akcea. ... 1, 700. Ionis | Akcea. Novartis. Exclusive option to licence. AKCEA-APOCIII-LRx for heart failure.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Medical Writer: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Medical Writer: Great salary and benefits

Digital Account Director: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Project Manager/ Account Manager: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Subscribe to our email news alerts

PMHub

Add my company

Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

International Childhood Cancer Day 2019: The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues: Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups: A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...